Cancer vaccine partners J&J, Aduro add $817M pact

Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But Johnson & Johnson ($JNJ) is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too--including lung cancer--and Thursday the companies announced a further $817 million deal. More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.